Clinical trial · Observational
Longitudinal Advanced Prostate Cancer Cohort (LAPCC)
NCT06067295CI-TRIAL-00105098recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 9, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260909-000002
Summary
Brief summary (as posted)
This study examines information from patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). By collecting biological samples (like blood, urine, and tissue), and health information (such as treatment, diet, and quality of life) researchers hope to learn more about prostate cancer and ways to improve outcomes in the future.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Carcinoma | Prostate Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Interventional Study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational
- description
- Patients undergo blood and urine sample collection, complete surveys, and have their medical records reviewed on study.
- interventionNames
- Other: Non-Interventional Study
Primary outcomes (1)
- measure
- Collection of biological specimens and clinical data for future research related to prostate cancer.
- timeFrame
- Up to 5 years
- description
- The objective of this study is to create a biorepository of biospecimen and clinical data. There is no primary clinical outcome for this study.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Men of all racial and ethnic groups 18 years of age or older * Men with a diagnosis of advanced (metastatic) prostate cancer who are scheduled to begin a new systemic treatment (including first or subsequent lines of therapy) * Prior participation on clinical trials is allowed Exclusion Criteria: * Inability to give informed consent * Any other malignancy, unless previously treated with curative intent and the subject has been disease free for 3 years or longer
References
Publications (0)
Data not yet available
No reference posted for this study.